anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to functional food with the action of blood sugar reduction and a preparation method of the functional food. The functional food with the action of blood sugar reduction The present invention relates to a functional food with the function of reducing blood sugar and its preparation method. Said preparation method includes the following steps: (1), pulverizing 2-4 portcan be prepared by the following method: 1) 2 to 4 portions of dry humifuse euphorbia herbs are taken and pulverized, water whose volume is 2 to 5 times of the volume of the dry humifuse euphorbia herions of dried humifuse euphorbia, adding water, boiling for 20-40 min, stirring and filtering, remaining filtrate, continuously boiling residue and repeating the above-mentioned steps, combining filtrb is added, and after the dry humifuse euphorbia herbs are boiled, boiling is kept for 20 to 40 minutes; a mixture of the dry humifuse euphorbia herb and the water is stirred continuously and filteredates; (2), extruding and dewatering ang-kak distillers' grains, mixing 1-1.5 portions of ang-kak distillers' grains with the above-mentioned humifuse euphorbia extract uniformly; and (3), vacuum-dryin, filter liquid is reserved, water of 1 to 3 times continues to be added in residue, and the residue is decocted; the steps are repeated, and finally, the filter liquid is merged; 2) 1 to 1.5 portionsg the above-mentioned mixture at 80 deg.C, pulverizing to obtain fine powder with 120 meshes so as to obtain the invented product.                                                                       of red infested rice grain stillage in which liquid is removed by extrusion is taken and is evenly mixed with humifuse euphorbia herb extraction liquid obtained in step 1), 3) a mixture of the red infested rice grain stillage and the humifuse euphorbia herb extraction liquid is dried in vacuum at the temperature of 80DEGC and is pulverized to fine powder of 120 meshes. The functional food with the action of blood sugar reduction can be capsules or tablets. The preparation method of the functional food with the action of blood sugar reduction is described. The present invention has the advantages of development of the blood sugar reduction function of the red infested rice grain stillage, changing of waste into valuable things, development of the humifuse euphorbia herb into the ingredient of health food for blood sugar reduction, simple formulation, cheap raw materials and simple manufacturing process; the humifuse euphorbia herbs can benefit to diabetic patients, and the compatibility of the humifuse euphorbia herbs and red infested rice grain stillage is proved to have good function of blood sugar reduction by experiments.
OBJECTIVE: This study aims to determine the elements of cardiovascular programs for risk management in elderly individuals with cardiac illness, with a focus on the features of the initiatives, advantages, and behavioral modification methodologies utilized.
MATERIALS AND METHODS: In November 2022, a systematic literature search was conducted following PRISMA recommendations. Researchers used the databases MEDLINE, CINAHL, Scopus, Web of Science, Cochrane, Academic Search Complete, as well as Mediclatina to conduct the research. The scholarly study population included 21 publications encompassing 26,040 patients with chronic diseases. The study took a qualitative approach to examine residents' use of phrases like "severe illness" and "non-communicable diseases," as well as terms connected to interventions like "programme development," "long-term care," and "community health planning." The results of the study were analyzed in terms of expected outcomes for cardiovascular disease in terms of behavior patterns, risk assessment, and co-morbidities.
RESULTS: The constituents, expertise fields of study associated, timeframe, as well as techniques employed vary across prevention strategies. The most common behavior modification methodologies are advice and negotiation.
CONCLUSIONS: In conclusion, the researcher describes that informative involvement is an agreed-upon method for controlling CVD threat in people with prolonged illnesses. The program's effectiveness cannot be determined due to the heterogeneity of the interventions. More research is required to improve the consistency of the results.
The genetic predisposition to lymphoma is not fully understood. We identified 13 lymphoma-cancer families (2011-2021), in which 27 individuals developed lymphomas and 26 individuals had cancers. Notably, male is the predominant gender in lymphoma patients, whereas female is the predominant gender in cancer patients (p = .019; OR = 4.72, 95% CI, 1.30-14.33). We collected samples from 18 lymphoma patients, and detected germline variants through exome sequencing. We found that germline protein truncating variants (PTVs) were enriched in DNA repair and immune genes. Totally, we identified 31 heterozygous germline mutations (including 12 PTVs) of 25 DNA repair genes and 19 heterozygous germline variants (including 7 PTVs) of 14 immune genes. PTVs of ATM and PNKP were found in two families, respectively. We performed whole genome sequencing of diffuse large B cell lymphomas (DLBCLs), translocations at IGH locus and activation of oncogenes (BCL6 and MYC) were verified, and homologous recombination deficiency was detected. In DLBCLs with germline PTVs of ATM, deletion and insertion in CD58 were further revealed. Thus, in lymphoma-cancer families, we identified germline defects of both DNA repair and immune genes in lymphoma patients.
Infants with viral bronchiolitis are currently treated with oxygen therapy if oxygen saturation is low. In earlier observational clinical studies, the use of high flow nasal cannulae therapy in infants with bronchiolitis has been associated with a decreased rate of intubation and intensive care. This study is a randomized controlled trial in five pediatric university hospitals in Finland comparing high flow nasal cannulae therapy to usual oxygen therapy in infants with bronchiolitis.

The investigators will recruit 160 infants who require oxygen therapy (oxygen saturation \<92%) during hospitalization due to a viral bronchiolitis. The participants are randomized to receive oxygen therapy either with high flow or ordinary nasal cannula.The infants are closely observed by study physicians for clinical parameters. The primary end point is treatment failure (need for change of respiratory support method). Secondary endpoints are respiratory rate (RR) and oxygen saturation (%) at specific measuring points, time from randomisation to end of oxygen therapy and time from randomisation to discharge.
BACKGROUND: The goal is to assess the role of immature granulocytes (IG) in the diagnosis of acute pelvic-inflammatory-disease (PID) and to determine whether they are useful for discriminating mild/moderate and severe PID.
METHODS: Patients admitted with the diagnosis of acute PID were retrospectively assessed. Diagnosis was based on CDC criteria. Patients were grouped as severe and mild/moderate PID based on need for hospitalization. Control group consisted of patients in whom PID was excluded by laparoscopy. Sample size was calculated with statistical methods. IGs were compared within the groups. Cutoff values were determined for prediction of diagnosis and severity of acute PID.
RESULTS: There were 74 severe, 32 mild/moderate acute PID, and 41 control patients. Thirty patients had surgery following no response to antibiotic treatment or tubo-ovarian abscess. IGs were significantly higher in the severe group compared to mild/moderate and control groups. ROC analysis showed IG counts (≥ 0.035 µL) and percentages (≥ 0.35%) were significantly effective in predicting acute PID and were associated with severity when they were ≥ 0.055 µL and ≥ 0.42%, respectively. IG count ≥ 0.085 was found to have 58.6% sensitivity and 63.1% speci-ficity for prediction of surgical intervention need.
CONCLUSIONS: IGs are components of simple CBC tests and are easily obtainable, cheap markers. They were found to be elevated in acute PID and correlated significantly with the severity of the disease. These markers may serve as adjunctive markers for the diagnosis of acute PID and may be useful in discrimination between mild/moderate and severe PID.
Voluntary healthy subjects will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.
Bupropion hydrochloride extended-release tablets (SR) can cause seizure. The risk of seizure is dose-related. The dose should not exceed 400 mg per day. Increase the dose gradually. Discontinue bupropion hydrochloride extended-release tablets (SR) and do not restart treatment if the patient experiences a seizure.

The risk of seizures is also related to patient factors, clinical situations, and concomitant medications that lower the seizure threshold. Consider these risks before initiating treatment with bupropion hydrochloride extended-release tablets (SR). Bupropion hydrochloride extended-release tablets (SR) are contraindicated in patients with a seizure disorder, current or prior diagnosis of anorexia nervosa or bulimia, or undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Contraindications ( 4), Drug Interactions ( 7.3)] . The following conditions can also increase the risk of seizure: severe head injury; arteriovenous malformation; CNS tumor or CNS infection; severe stroke; concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids); metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia); use of illicit drugs (e.g., cocaine); or abuse or misuse of prescription drugs such as CNS stimulants. Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin; use of anorectic drugs; and excessive use of alcohol, benzodiazepines, sedative/hypnotics, or opiates. 

Incidence of Seizure with Bupropion Use: When bupropion hydrochloride extended-release tablets (SR) are dosed up to 300 mg per day, the incidence of seizure is approximately 0.1% (1/1,000) and increases to approximately 0.4% (4/1,000) at the maximum recommended dose of 400 mg/day. 

The risk of seizure can be reduced if the dose of bupropion hydrochloride extended-release tablets (SR) does not exceed 400 mg/day, given as 200 mg twice daily, and the titration rate is gradual.
Hepatic veno-occlusive disease (VOD)/sinusoidal obstructive syndrome (SOS) is a severe complication that can occur following haematopoietic stem cell transplant (HSCT) with high-intensity conditioning chemotherapy regimens. Severe VOD/SOS, often characterised by multiorgan failure, is associated with a high mortality rate. This case report details the complex clinical course of a male patient in his mid-20s, recently diagnosed with B cell acute lymphoblastic leukaemia, who underwent allogeneic HSCT. Based on the 2023 European Society for Blood and Marrow Transplantation (EBMT) criteria, the patient developed very severe VOD/SOS, prompting immediate treatment with defibrotide. Unexpectedly, he developed profound hyperammonaemia exceeding 900 µmol/L, leading to encephalopathy and cerebral oedema. Despite aggressive interventions including defibrotide, lactulose, rifampin and haemodialysis, the patient passed away due to cerebral oedema and pulseless electrical activity arrest. We theorise the hyperammonaemia is disproportionate to his hepatic dysfunction and is possibly secondary to an acquired defect of the urea synthesis consistent with idiopathic hyperammonaemia, a rare complication in patients receiving intense conditioning chemotherapy.
The technique of dialysis has seen enormous advancements over the past fifty years, evolving from an initial phase, primarily based on diffusion through a semipermeable membrane to the current preference for high-efficiency convection, involving the removal of several liters of ultrafiltrate. Diffusive dialysis, due to its relative simplicity in execution, has allowed the treatment of millions of individuals with ESRD, ensuring them a certain quality of life. However, it is not considered optimal in terms of survival and has some complications inherent to the uremic state. Convection, by removing toxic substances through solvent drag, has enabled the purification of not only small molecules but also medium-to-large molecular weight molecules. As a result, hemodiafiltration techniques have shown improvements in both mortality and intradialytic complications such as cramps and intradialytic hypotension. These results, however, involve fluid exchanges that far exceed 20 liters per session, thus increasing technical complexity and not being applicable to all patients, particularly those with vascular access problems. The recent discovery of so-called medium cut-off (MCO) membranes appears to maintain the benefits of hemodiafiltration techniques without the need for high convective flows. Therefore, the debate between convection and diffusion seems far from over and may hold more surprises in the near future.
The INTERCEPT treatment process uses amustaline and glutathione together with a processing solution in a single-use disposable set and results in pathogen and leukocyte inactivated RBCs suspended in SAG-M additive solution (INTERCEPT RBCs). The INTERCEPT treatment will be performed on leukocyte reduced RBC components prepared from whole blood collections and suspended in AS-5 additive solution within 24 hours of collection. The test component is allogeneic INTERCEPT RBCs suspended in SAG-M and stored at 1°C to 6 for up to 35 days post-donation and administered intravenously. Dose and schedule of RBC transfusions will be determined by the treating physician.
PURPOSE:To obtain an emulsified or solubilized flavor composition having excellent stability, by emilsifying or solubilizing a water-insoluble or hardly soluble flavor with a solution of a polyhydroxy compound in the presence of (decom- posed) protein and/or a surface active agent. CONSTITUTION:The titled flavor composition is prepared by emulsifying or solubilizing a water-insoluble or hardly soluble flavor such as linseed oil, cinnamon oil, garlic oil, etc. with a polyhydroxy compound (e.g. glycerin, sorbitol,  sucrose, etc.) or its aqueous solution in the presence of proteins, decomposed  proteins (e.g. meat powder, sodium caseinate, yeast extract, etc.) and/or a surface active agent (anionic, nonionic, cationic, amphoteric surface active agent,  etc.). The obtained flavor composition is suitable as a flavor of perfume, soap,  refreshing drink, liquor, etc.
The invention provides application of a seaweed and a seaweed derivative in preparing a medicament for treating depression and the prepared antidepressant medicament. The application dosage is 0.01-30mg of the glabrous greenbrier rhizome or the derivatives thereof per kilogram of body weight, and the antidepressant effect can be generated within 60 minutes after administration. After 5 days of administration, both low and high doses produced significant antidepressant effects. The research result of the invention shows that, in the mammal mouse tail suspension experiment, the seaweed or the derivatives thereof have the effect of rapidly resisting depression and are more effective than the conventional antidepressant imipramine. The invention adopts a forced swimming experiment and a mouse tail suspension experiment as drug screening experiments, and simultaneously carries out a mouse Open field experiment (Open field test) so as to test the autonomous activity of the mice and avoid the interference of central stimulants. The antidepressant has the advantages of remarkable antidepressant effect, quick response, small dosage, small side effect and the like, and is expected to become a novel antidepressant with quick, efficient and novel mechanism.
Variants in the CNNM2 gene are causative for hypomagnesaemia, seizures and intellectual disability, although the phenotypes can be variable. This study aims to understand the genotype-phenotype relationship in affected individuals with CNNM2 variants by phenotypic, functional and structural analysis of new as well as previously reported variants. This results in the identification of seven variants that significantly affect CNNM2-mediated Mg2+ transport. Pathogenicity of these variants is further supported by structural modelling, which predicts CNNM2 structure to be affected by all of them. Strikingly, seizures and intellectual disability are absent in 4 out of 7 cases, indicating these phenotypes are caused either by specific CNNM2 variant only or by additional risk factors. Moreover, in line with sporadic observations from previous reports, CNNM2 variants might be associated with disturbances in parathyroid hormone and Ca2+ homeostasis.
Chronic kidney disease (CKD) represents a significant and escalating global health challenge, with morbidity and mortality rates rising steadily. Evidence increasingly implicates perirenal adipose tissue (PRAT) deposition as a contributing factor in the pathogenesis of CKD. This review explores how PRAT deposition may exert deleterious effects on renal structure and function. The anatomical proximity of PRAT to the kidneys not only potentially causes mechanical compression but also leads to the dysregulated secretion of adipokines and inflammatory mediators, such as adiponectin, leptin, visfatin, tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and exosomes. Additionally, PRAT deposition may contribute to renal lipotoxicity through elevated levels of free fatty acids (FFA), triglycerides (TAG), diacylglycerol (DAG), and ceramides (Cer). PRAT deposition is also linked to the hyperactivation of the renin-angiotensin-aldosterone system (RAAS), which further exacerbates CKD progression. Recognizing PRAT deposition as an independent risk factor for CKD underscores the potential of targeting PRAT as a novel strategy for the prevention and management of CKD. This review further discusses interventions that could include measuring PRAT thickness to establish a baseline, managing metabolic risk factors that promote its deposition, and inhibiting key PRAT-induced signaling pathways.
Empowered Relief is a 2-hour one session pain relief skills intervention that is delivered to a group of patients by a certified instructor using a standardized treatment manual and electronic slide deck. Content includes completion of a pain survey, pain neuroscience education, information on pain and stress responses, experiential exercises, information on three core pain management skills, completion of a personalized plan for empowered relief, and receipt of a binaural app for daily use.
Acyclovir cream was evaluated in two double-blind, randomized, placebo (vehicle)-controlled trials for the treatment of recurrent herpes labialis. The average patient had five episodes of herpes labialis in the previous 12 months. In the first trial, the median age of subjects was 37 years (range 18 to 81 years), 74% were female, and 94% were Caucasian. In the second trial, median age of subjects was 38 years (range 18 to 87 years), 73% were female, and 94% were Caucasian. Subjects were instructed to initiate treatment within 1 hour of noticing signs or symptoms and continue treatment for 4 days, with application of study medication 5 times per day. In both studies, the mean duration of the recurrent herpes labialis episode was approximately one-half day shorter in the subjects treated with acyclovir cream (n = 682) compared with subjects treated with placebo (n = 703) for approximately 4.5 days versus 5 days, respectively. No significant difference was observed between subjects receiving acyclovir cream or placebo in the prevention of progression of cold sore lesions.
No human overdosage data are available for CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE.

Codeine

Overdosage with codeine is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdosage, apnea, circulatory collapse, cardiac arrest, and death may occur.

Codeine may cause miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings). Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations.

Chlorpheniramine

Manifestations of chlorpheniramine overdosage may vary from central nervous system depression to stimulation. Central toxic effects are characterized by agitation, anxiety, delirium, disorientation, hallucinations, hyperactivity, sedation, and seizures. Severe overdosage may produce coma, medullary paralysis, and death. Peripheral toxicity includes hypertension, tachycardia, dysrhythmias, vasodilation, hyperpyrexia, mydriasis, urinary retention, and diminished gastrointestinal motility. Dry mouth, pharynx, bronchi, and nasal passages may be observed.

Impaired secretion from sweat glands following toxic doses of drugs with anticholinergic side effects may predispose to hyperthermia.

An adult ingested 400 mg chlorpheniramine with no reported serious adverse effects. Toxic psychosis, a possible class effect from overdose of sedating antihistamines, has been reported with accidental overdose of chlorpheniramine.

Treatment of overdosage consists of discontinuation of CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE together with institution of appropriate therapy. 

Give primary attention to re-establishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The opioid antagonist naloxone hydrochloride is a specific antidote for respiratory depression that may result from overdosage or unusual sensitivity to opioids including codeine. Therefore, an appropriate dose of naloxone hydrochloride should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. For further information, see full prescribing information for naloxone hydrochloride. An antagonist should not be administered in the absence of clinically significant respiratory or circulatory depression. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Gastric emptying may be useful in removing unabsorbed drug. 

Hemodialysis is not routinely used to enhance the elimination of codeine or chlorpheniramine from the body. Urinary excretion of chlorpheniramine is increased when the pH of the urine is acidic; however, acid diuresis is NOT recommended to enhance elimination in overdose, as the risks of acidemia and acute tubular necrosis in patients with rhabdomyolysis far outweigh any potential benefits.
B. Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.
Participants receive a placebo PO BID for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
Placebo + exercise. Patients will ingest 200ml of placebo (water, without nitrate (NO3-)), and after 2 hours they will be instructed to perform an exercise protocol.